GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Macro Group Pharmaceuticals (Macro Capital) Co (CAI:MCRO) » Definitions » ROE %

Macro Group Pharmaceuticals (Macro Capital) Co (CAI:MCRO) ROE % : 235.21% (As of Sep. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Macro Group Pharmaceuticals (Macro Capital) Co ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Macro Group Pharmaceuticals (Macro Capital) Co's annualized net income for the quarter that ended in Sep. 2024 was E£90.7 Mil. Macro Group Pharmaceuticals (Macro Capital) Co's average Total Stockholders Equity over the quarter that ended in Sep. 2024 was E£38.6 Mil. Therefore, Macro Group Pharmaceuticals (Macro Capital) Co's annualized ROE % for the quarter that ended in Sep. 2024 was 235.21%.

The historical rank and industry rank for Macro Group Pharmaceuticals (Macro Capital) Co's ROE % or its related term are showing as below:

CAI:MCRO' s ROE % Range Over the Past 10 Years
Min: 6.64   Med: 41.85   Max: 42.36
Current: 6.64

During the past 3 years, Macro Group Pharmaceuticals (Macro Capital) Co's highest ROE % was 42.36%. The lowest was 6.64%. And the median was 41.85%.

CAI:MCRO's ROE % is ranked worse than
50.79% of 1841 companies
in the Consumer Packaged Goods industry
Industry Median: 6.8 vs CAI:MCRO: 6.64

Macro Group Pharmaceuticals (Macro Capital) Co ROE % Historical Data

The historical data trend for Macro Group Pharmaceuticals (Macro Capital) Co's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Macro Group Pharmaceuticals (Macro Capital) Co ROE % Chart

Macro Group Pharmaceuticals (Macro Capital) Co Annual Data
Trend Dec20 Dec21 Dec22
ROE %
- 41.34 42.36

Macro Group Pharmaceuticals (Macro Capital) Co Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Jun23 Sep23 Jun24 Sep24
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 40.25 17.19 59.15 -17.37 235.21

Competitive Comparison of Macro Group Pharmaceuticals (Macro Capital) Co's ROE %

For the Household & Personal Products subindustry, Macro Group Pharmaceuticals (Macro Capital) Co's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Macro Group Pharmaceuticals (Macro Capital) Co's ROE % Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Macro Group Pharmaceuticals (Macro Capital) Co's ROE % distribution charts can be found below:

* The bar in red indicates where Macro Group Pharmaceuticals (Macro Capital) Co's ROE % falls into.



Macro Group Pharmaceuticals (Macro Capital) Co ROE % Calculation

Macro Group Pharmaceuticals (Macro Capital) Co's annualized ROE % for the fiscal year that ended in Dec. 2022 is calculated as

ROE %=Net Income (A: Dec. 2022 )/( (Total Stockholders Equity (A: Dec. 2021 )+Total Stockholders Equity (A: Dec. 2022 ))/ count )
=173.836/( (357.863+462.833)/ 2 )
=173.836/410.348
=42.36 %

Macro Group Pharmaceuticals (Macro Capital) Co's annualized ROE % for the quarter that ended in Sep. 2024 is calculated as

ROE %=Net Income (Q: Sep. 2024 )/( (Total Stockholders Equity (Q: Jun. 2024 )+Total Stockholders Equity (Q: Sep. 2024 ))/ count )
=90.716/( (27.228+49.907)/ 2 )
=90.716/38.5675
=235.21 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Sep. 2024) net income data. ROE % is displayed in the 30-year financial page.


Macro Group Pharmaceuticals (Macro Capital) Co  (CAI:MCRO) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Sep. 2024 )
=Net Income/Total Stockholders Equity
=90.716/38.5675
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(90.716 / 655.824)*(655.824 / 546.224)*(546.224 / 38.5675)
=Net Margin %*Asset Turnover*Equity Multiplier
=13.83 %*1.2007*14.1628
=ROA %*Equity Multiplier
=16.61 %*14.1628
=235.21 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Sep. 2024 )
=Net Income/Total Stockholders Equity
=90.716/38.5675
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (90.716 / 91.004) * (91.004 / 133.068) * (133.068 / 655.824) * (655.824 / 546.224) * (546.224 / 38.5675)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.9968 * 0.6839 * 20.29 % * 1.2007 * 14.1628
=235.21 %

Note: The net income data used here is four times the quarterly (Sep. 2024) net income data. The Revenue data used here is four times the quarterly (Sep. 2024) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Macro Group Pharmaceuticals (Macro Capital) Co ROE % Related Terms

Thank you for viewing the detailed overview of Macro Group Pharmaceuticals (Macro Capital) Co's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Macro Group Pharmaceuticals (Macro Capital) Co Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
83, Al Moltaka Al Arabi, Sheraton, Cairo, EGY
Macro Group Pharmaceuticals (Macro Capital) Co is principally engaged in the manufacture and sale of cosmeceutical and ventured into nutraceutical products.

Macro Group Pharmaceuticals (Macro Capital) Co Headlines